Central adrenal insufficiency: who, when, and how? From the evidence to the controversies - an exploratory review

Arch Endocrinol Metab. 2022;66(4):541-550. doi: 10.20945/2359-3997000000493. Epub 2022 Jun 23.

Abstract

Central adrenal insufficiency (CAI) is a life-threatening disorder. This occurs when ACTH production is insufficient, leading to low cortisol levels. Since corticosteroids are crucial to many metabolic responses under organic stress and inflammatory conditions, CAI recognition and prompt treatment are vital. However, the diagnosis of CAI is challenging. This is not only because its clinical presentation is usually oligosymptomatic, but also because the CAI laboratory investigation presents many pitfalls. Thus, the clarification of when to use each test could be helpful in many contexts. The CAI challenge is also involved in treatment: Several formulations of synthetic steroids exist, followed by the lack of a biomarker for glucocorticoid replacement. This review aims to access all available literature to synthesize important topics about who should investigate CAI, when it should be suspected, and how CAI must be treated.

Keywords: ACTH deficiency; Central adrenal insufficiency; cortisol replacement; glucocorticoid replacement; secondary adrenal insufficiency.

Publication types

  • Review

MeSH terms

  • Adrenal Insufficiency* / drug therapy
  • Adrenal Insufficiency* / therapy
  • Biomarkers
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydrocortisone*

Substances

  • Biomarkers
  • Glucocorticoids
  • Hydrocortisone